
Work Here?
OpenEvidence builds AI-driven clinical decision support tools that help healthcare professionals make better choices at the point of care. It creates AI models and interfaces that integrate with existing platforms (notably through Mayo Clinic Platform Accelerate) and partner ecosystems like Elsevier Health to power products such as ClinicalKey AI. Clinicians use these tools inside their regular clinical workflows, with AI assisting by analyzing medical literature, guidelines, and patient data to suggest evidence-based options.
Industries
Data & Analytics
AI & Machine Learning
Healthcare
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$967M
Headquarters
Miami, Florida
Founded
2022
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$967M
Above
Industry Average
Funded Over
7 Rounds
Meal Benefits
Commuter Benefits
OneOncology and openevidence partner to improve cancer care nationwide. MIAMI & NASHVILLE, Tenn.-(BUSINESS WIRE)-#Oncology-OpenEvidence, the most widely used AI-powered medical search and clinical decision-support platform, and OneOncology, a physician-led national platform empowering independent medical specialty practices, today announced a partnership to embed OpenEvidence into certain clinical applications used across OneOncology's platform to enable physicians to use OpenEvidence for clinical evidence retrieval, reference and research. The integration is designed to make it easier for physicians at OneOncology partner practices to access OpenEvidence directly within their clinical workflows. Over time, the collaboration is expected to expand to include deeper integration with OneOncology's structured genomic data assets and clinical trials matching systems - further aligning evidence, precision oncology insights, and research opportunities at the point of care. In the United States, more than half of hematology/oncology physicians already use OpenEvidence to help inform their clinical decisions. Community physicians at OneOncology partner practices deliver modern, high-quality care to 1.5 million patients nationwide. More than 50 percent of cancer patients in the United States receive their care in community oncology practices. Community physicians manage hundreds of approved therapies across dozens of tumor types, navigate biomarker-driven treatment algorithms that shift with each new approval, and increasingly offer clinical trials that were once limited to academic centers. "Independent physicians across the OneOncology network treat a wide array of cancers across stages, bringing the latest research and treatment options to patients close to home," said Davey Daniel, MD, OneOncology's Chief Medical Officer. "As physicians who read constantly and stay engaged with emerging science, OpenEvidence will help our partners efficiently access the latest, best-available research and evidence, improving the physician experience and supporting better patient outcomes." "Integrating OpenEvidence directly into my workflow will make it easier to access the information I need at the point of care," said Emily Z. Touloukian, DO, FASCO, President and CEO of Coastal Cancer Center in Myrtle Beach, SC. "Oncology is where the information problem in medicine is most acute: the literature moves fast, treatment decisions are increasingly personalized, and the stakes are as high as they get," said Dr. Travis Zack, Chief Medical Officer of OpenEvidence. "OneOncology's partner practice physicians have built a network that brings clinical trials, leading treatment pathways and physician-led innovation into the community. Building OpenEvidence directly into that workflow means the latest evidence, OneOncology's treatment pathways and relevant trials all converge at the point of care." About OpenEvidence OpenEvidence is the fastest-growing and most widely-used clinical decision support platform and medical search engine among U.S. clinicians. According to independent studies, more American physicians use OpenEvidence than all other AI platforms combined. OpenEvidence is trusted by millions of verified healthcare professionals to make high-stakes clinical decisions at the point of care that are sourced, cited, and grounded in peer-reviewed medical literature. Founded with the mission to organize and expand the world's collective medical knowledge, OpenEvidence is actively used daily, on average, by the majority of physicians in the United States. OpenEvidence is free for all verified U.S. clinicians. Learn more at openevidence.com. About OneOncology OneOncology was founded by community physicians, for community physicians, with the mission of improving the lives of everyone living with cancer and other diseases. Its goal is to enable community medical practices to remain independent and to improve patient access to care in their communities, all at a lower cost than in the hospital setting. OneOncology supports its platform of community medical practices through group purchasing, operational optimization, practice growth, and clinical innovation. Its partner practices comprise approximately 2,300+ providers who care for approximately 1.5 million patients across 20 states. To learn more, visit oneoncology.com.
OpenEvidence launches new Education Platform offering continuing education (CE) and Maintenance of Certification (MOC) credit. MIAMI-(BUSINESS WIRE)-#CME-OpenEvidence, the leading AI-powered medical search and decision support platform, has launched a new education platform offering accredited, interprofessional continuing education (CE) and Maintenance of Certification (MOC) credits for NPI-verified physicians, nurse practitioners, and physician associates. Physicians can additionally earn Maintenance of Certification (MOC) credit through select certifying boards. As AI-powered clinical tools become increasingly common, it is essential that accredited CE keeps pace with the evolving reality of practice. The OpenEvidence Education Platform is powered by the same underlying models that support OpenEvidence, adapted to create personalized, accredited learning experiences for clinicians. Designed to bridge the gap between point-of-care practice and CE, the new accredited learning experience draws on each clinician's routine use of OpenEvidence. Clinicians often use OpenEvidence in the context of a patient case, clinical uncertainty, or a specific question arising in practice. The new learning experience builds on that engagement by inviting clinicians to reflect on what they learned from their interactions with searched-for material, and by linking those reflections to the content blueprints and requirements of participating certifying boards. The experience recognizes learning when clinicians engage with evidence-based content, consider its relevance to practice, identify a key learning point, and document reflection on how the information informs their clinical reasoning, knowledge, or future care decisions. This creates a more natural bridge between real-world information needs, accredited CE, and continuing certification. "The best learning in medicine comes from real patient care. We designed this experience around that principle, connecting clinical context, searched-for evidence, and reflective learning to the competencies defined by certifying boards," said Mondira Ray, MD, MBI, Senior Vice President of Clinical Informatics at OpenEvidence. "Our goal was to make earning CE and MOC credit feel like a natural and meaningful extension of clinical practice, not an added task." "What is particularly compelling is the depth of personalization," said Vishal Patel, MD, Vice President of Clinical Partnerships and AI Education at OpenEvidence. "Each activity is grounded in the educational framework of the clinician's specialty board, helping ensure that learning prompted by real clinical questions is connected to the knowledge and competencies most relevant to that clinician's practice." "We are excited to be collaborating on this robust platform as the accredited provider of the continuing education and certification learning experience associated with this cutting-edge tool, using AI effectively and responsibly," stated Dorothy Caputo, MA, BSN, RN, President of AKH, Inc., Advancing Knowledge in Healthcare. OpenEvidence is used by clinicians across every specialty and practice setting to bring high-quality, evidence-based decision support to the point of care. This new experience marks a shift toward a more individualized, streamlined, and practice-integrated model for accredited CE and continuing certification. It is available today at no cost to all NPI-verified physicians, nurse practitioners, and physician associates. Physicians completing their CME requirements can also track CME earned through OpenEvidence on the Accreditation Council for Continuing Medical Education's CME Passport(R) platform, where they can generate transcripts and monitor completion of state relicensing CME requirements. To learn more, visit openevidence.com/cme. About Accreditation: In support of improving patient care, this activity has been planned and implemented by AKH, Inc., Advancing Knowledge in Healthcare and OpenEvidence. AKH, Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. About OpenEvidence OpenEvidence is the most widely used medical AI platform among U.S. physicians and is trusted by hundreds of thousands of verified clinicians to support clinical decisions at the point of care with answers that are sourced, cited, and grounded in peer-reviewed medical literature. OpenEvidence was founded with the mission to organize and expand the world's collective medical knowledge. Learn more at openevidence.com.
OpenEvidence is reportedly seeking $200 million in new funding at a $20 billion valuation, highlighting continued investor confidence in AI-powered clinical decision support platforms.
Boston Children's Hospital and OpenEvidence collaborate to advance ai-powered analysis of Clinical practice patterns. MIAMI & BOSTON-(BUSINESS WIRE)-#medicalAI-Boston Children's Hospital, one of the nation's top pediatric hospitals, and OpenEvidence, the leading AI-powered clinical decision support platform, today announced a multi-year collaboration to examine how clinicians' real-world use of AI tools at the point of care relates to practice patterns and delivery of care. OpenEvidence has seen broad adoption in clinical settings, yet little is known about how that adoption relates to clinical practice patterns at a population level. By bringing together one of the leading pediatric academic medical centers at the forefront of clinical innovation with the most widely used medical AI platform, the collaboration is positioned to evaluate the relationship between OpenEvidence and real-world clinical practice at a scale and resolution not previously possible. To ensure patient privacy, the teams will focus on analyzing only aggregated, provider-level data; no patient-level data will be accessed or used. "This initiative brings together Boston Children's deep clinical expertise and OpenEvidence's clinical evidence platform to better understand care delivery and help children thrive, while preserving patient privacy," said John Brownstein, PhD, Chief Innovation Officer at Boston Children's Hospital. "OpenEvidence has quickly become a trusted, everyday resource at the point of care, supporting millions of patient visits across the U.S. By analyzing anonymous patterns in how clinicians ask and answer questions during these encounters, we can surface insights into health trends that would otherwise remain hidden - and, in collaboration with OpenEvidence, continue helping clinicians deliver better care." The collaboration includes an integration that enables Boston Children's clinicians to access OpenEvidence directly within the electronic health record, reflecting how central the tool has become to clinical workflows at Boston Children's. "As a pediatrician who trained and practiced at Boston Children's before joining OpenEvidence, I have watched the tool go from nonexistent to indispensable among my colleagues in a remarkably short period of time," said Mondira Ray, MD, MBI, Senior Vice President of Clinical Informatics at OpenEvidence. "OpenEvidence has become part of how clinicians practice. A change this visible carries implications we are eager to examine." Boston Children's Hospital is ranked among the best children's hospitals in the nation by U.S. News & World Report and is a pediatric teaching affiliate of Harvard Medical School. Home to the world's largest research enterprise based at a pediatric medical center, Boston Children's has led the way in life-changing pediatric innovation since its founding in 1869. Today, 3,000 researchers and scientific staff, including 15 members of the National Academy of Sciences, 37 members of the National Academy of Medicine and 13 Howard Hughes Medical Investigators across ~1M square feet of lab space comprise the research community. From bench to bedside, scientists work on preventing, treating, and curing diseases that impact both children and adults, no matter how rare or complex the condition. Founded as a 20-bed hospital for children, Boston Children's is now a 491-bed comprehensive center for pediatric and adolescent health care. With nine satellite locations and the Martha Elliot Health Center, Boston Children's also provides 24/7 pediatric care at five hospitals including Beverly Hospital, Winchester Hospital, St. Luke's Hospital, South Shore Hospital and Cape Cod Hospital. Boston Children's also includes: Affiliation with Franciscan Children's Hospital, including 112 beds and 700+ employees; Boston Children's Primary Care Alliance, a robust network of 33 pediatric practices serving patients and families throughout Massachusetts; The Pediatric Physicians' Organization at Boston Children's Hospital (PPOC) with more than 400 physicians, nurse practitioners, and physician assistants devoted exclusively to pediatric primary care, in close collaboration with subspecialists at Boston Children's in more than 90 locations throughout Massachusetts; Boston Children's Health Physicians (BCHP) which is the largest pediatric multispecialty group in New York's Metropolitan Area, the Hudson Valley, and Connecticut, including nearly 300 clinicians in more than 60 locations. About OpenEvidence OpenEvidence is the fastest-growing and most widely-used clinical decision support platform in the United States, and the most widely used medical search engine among U.S. clinicians. OpenEvidence is trusted by hundreds of thousands of verified healthcare professionals to make high-stakes clinical decisions at the point of care that are sourced, cited, and grounded in peer-reviewed medical literature. Founded with the mission to organize and expand global medical knowledge, OpenEvidence is actively used daily, on average, by the majority of physicians in the United States. Learn more at openevidence.com July 16th, 2026 July 15th, 2026
OpenEvidence, Boston Children's partner to study AI's impact on clinical care. OpenEvidence's AI will be integrated into the health system's EHR in order for the pair to study how clinicians' use of AI at the point of care affects care delivery patterns. OpenEvidence, an AI-enabled medical research aggregation platform for doctors, announced a multi-year collaboration with Boston Children's Hospital to evaluate how providers' AI use at the point of care correlates with care delivery patterns. Florida-based OpenEvidence offers a free medical information platform that includes an AI-powered medical copilot for doctors in the U.S. trained only on medical journals and medical data. The platform aggregates and synthesizes clinical information with the aim to help doctors make more evidence-based decisions. The partners aim to examine the relationship between use of OpenEvidence and clinical practice patterns at scale by analyzing aggregated provider data. OpenEvidence said in a statement that no patient data will be accessed or used. Boston Children's providers will have access to OpenEvidence directly within the EHR. "This initiative brings together Boston Children's deep clinical expertise and OpenEvidence's clinical evidence platform to better understand care delivery and help children thrive, while preserving patient privacy," John Brownstein, chief innovation officer at Boston Children's Hospital, said in a statement. "By analyzing anonymous patterns in how clinicians ask and answer questions during these encounters, we can surface insights into health trends that would otherwise remain hidden - and, in collaboration with OpenEvidence, continue helping clinicians deliver better care." THE LARGER TREND Earlier this week, OpenEvidence announced a collaboration with the American Academy of Pediatrics (AAP). Clinicians will be able to obtain answers on AAP policies, recommendations and pediatric research through OpenEvidence, with citations to original sources. The company has announced numerous other partnerships with organizations to integrate their expertise into the OpenEvidence AI platform, including the Anticoagulation Forum, the Journal of Medical Insight, the Global Initiative for Asthma, the American Academy of Ophthalmology, the American Society of Clinical Oncology and the American College of Obstetricians & Gynecologists, among others. This year alone, OpenEvidence has also unveiled numerous partnerships to provide clinicians with access to its AI platform, including collaborations with Cedars-Sinai Health System, Mount Sinai Health System, Sutter Health, NewYork-Presbyterian and its affiliated medical schools, Columbia University Vagelos College of Physicians and Surgeons, and Weill Cornell Medicine. In January, OpenEvidence closed a $250 million Series D funding round, bringing its total raise to nearly $700 million over the past 12 months and doubling its valuation to $12 billion. In October 2025, OpenEvidence scored $200 million in a Series C round, boosting its valuation to $6 billion. In July of last year, the company secured $210 million in Series B funding at a $3.5 billion valuation and raised approximately $75 million in Series A funding in February 2025 at a $1 billion valuation, bringing it to unicorn status.
Find jobs on Simplify and start your career today
Industries
Data & Analytics
AI & Machine Learning
Healthcare
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$967M
Headquarters
Miami, Florida
Founded
2022
Find jobs on Simplify and start your career today